.Pharmacolibrary.Drugs.ATC.L.L01EL02 .Pharmacolibrary.Drugs.ATC.L.L01EL02| name: | Acalabrutinib |
| ATC code: | L01EL02 | route: | oral |
| n-compartments | 2 |
Acalabrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor used for the treatment of B-cell malignancies, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). It is approved for use in several countries including the USA and EU.
Pharmacokinetic parameters reported for adult patients with B-cell malignancies after oral administration under fasting conditions.
Eyre, TA, et al., & Hillmen, P (2021). Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. The Lancet. Haematology 8(12) e912–e921. DOI:10.1016/S2352-3026(21)00305-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34735860